Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol

Citation
Sun. Singh et al., Inhibition of dioxin effects on bone formation in vitro by a newly described aryl hydrocarbon receptor antagonist, resveratrol, J ENDOCR, 167(1), 2000, pp. 183-195
Citations number
73
Categorie Soggetti
Endocrinology, Nutrition & Metabolism
Journal title
JOURNAL OF ENDOCRINOLOGY
ISSN journal
00220795 → ACNP
Volume
167
Issue
1
Year of publication
2000
Pages
183 - 195
Database
ISI
SICI code
0022-0795(200010)167:1<183:IODEOB>2.0.ZU;2-7
Abstract
Aryl hydrocarbon receptor (AhR) ligands are environmental contaminants foun d in cigarette smoke and other sources of air pollution. The prototypical c ompound is TCDD (2,3,7,8-tetrachlorodibenzo-p-dioxin), also known as dioxin . There is an increasing body of knowledge linking cigarette smoking to ost eoporosis and periodontal disease, but the direct effects of smoke-associat ed aryl hydrocarbons on bone are not well understood. Through the use of re sveratrol (3,5,4'-trihydroxystilbene), a plant antifungal compound that we have recently demonstrated to be a pure AhR antagonist, we have investigate d the effects of TCDD on osteogenesis. It was postulated that TCDD would in hibit osteogenesis in bone-forming cultures and that this inhibition would be antagonized by resveratrol. We employed the chicken periosteal osteogene sis (CPO) model, which has been shown to form bone in vitro in a pattern mo rphologically and biochemically similar to that seen in vivo, as well as a rat stromal cell bone nodule formation model. In the CPO model, alkaline ph osphatase (AP) activity was reduced by up to 50% (P<0.01 vs control) in the presence of 10(-9) M TCDD and these effects were reversed by 10(-6) M resv eratrol (P<0.05 vs TCDD alone). TCDD-mediated inhibition of osteogenesis wa s restricted primarily to the osteoblastic differentiation phase (days 0-2) as later addition did not appear to have any effects. Message levels for i mportant bone-associated proteins (in the CPO model) such as collagen type I, osteopontin, bone sialoprotein and AP were inhibited by TCDD, an effect that was antagonized by resveratrol. Similar findings were obtained using t he rat stromal bone cell line. TCDD (at concentrations as low as 10(-10) M) caused an approximately 33% reduction in AP activity, which was abrogated by 3.5 x 10(-7) M resveratrol. TCDD also induced a marked reduction in mine ralization (similar to 75%) which was completely antagonized by resveratrol . These data suggest that AhR ligands inhibit osteogenesis probably through inhibition of osteodifferentiation and that this effect can be antagonized by resveratrol. Since high levels of AhR ligands are found in cigarette sm oke, and further since smoking is an important risk factor in both osteopor osis and periodontal disease, it may be postulated that AhR ligands are the component of cigarette smoke linking smoking to osteoporosis and periodont al disease. If so, resveratrol could prove to be a promising preventive or therapeutic agent for smoking-related bone loss.